Menu

Recent Interviews

Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)

info@saturnoil.com

+1-587-392-7900

Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"


Gary Cope, President and CEO, Barsele Minerals

Gary Cope
President and CEO | Barsele Minerals
Suite 1130 - 1055 W. Hastings Street, V6E 2E9 Vancouver (CAN)

info@barseleminerals.com

+1(604) 687-8566

Interview Barsele Minerals: 'I have never seen a project with such good general conditions'.


19. July 2021 | 11:11 CET

BioNTech, Defence Therapeutics, Siemens Healthineers - Winning the fight against cancer

  • Biotechnology
Photo credits: pixabay.com

There are over 200 different types of cancer where degenerate cells begin to form tumors. The cost of the disease is estimated at USD 1,160,000,000,000 worldwide. It is no wonder that a lot of money goes into researching cancer drugs. Whoever makes the breakthrough here can make a lot of money. It would be desirable that one of the three companies presented today could find a solution, as that could save 9.6 million people a year. But it is not only drugs that promise profits but also prevention and diagnostics. Today we highlight three companies that have joined the fight against cancer.

time to read: 4 minutes by Armin Schulz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , DEFENCE THERAPEUTICS INC | CA24463V1013 , SIEMENS HEALTH.AG NA O.N. | DE000SHL1006


 

Author

Armin Schulz

Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

About the author


BioNTech - Phase II launched in skin cancer patients

When the name BioNTech comes up, most people think directly of the Corona vaccine. The Company stated at the time of the Delta variant outbreak that the vaccine would also protect against it. Since a study published from Israel found only 64% efficacy against the delta variant, boosting via another dose has become a hot topic. The booster is intended to restore protection. On the one hand, this means that the vaccination will probably have to be renewed every 6 months; on the other hand, this is positive for the shareholders since more vaccines will also be needed.

The Mainz-based biotech Company announced on June 18 that its anti-cancer vaccine would be tested in humans for the first time in a phase II trial. The trial group consists of 120 skin cancer patients and is designed to uncover efficacy and potential side effects. Again, the mRNA method will be used to help the body's defense system fight the degenerated cells. Specific proteins can be used to identify the bad cells. Four other cancer drugs are still in the pipeline.

Covid-19 has opened the door for the new technology, and now they are trying to fight other diseases through this technology. Without the study from Israel, the share would undoubtedly have seen new highs by now. The uncertainty caused a small price slide from EUR 199 to EUR 163. A double bottom has now been formed there; however, the prospect of more vaccine sales has lured investors again. Last Friday, the share exited trading at EUR 193.75.

Defence Therapeutics - A promising approach

The Canadian biotech company has set itself the goal of developing innovative treatment solutions for all people. The basis for this is formed by two different technologies, which the Company owns 100%. There are three main products currently in development based on the Company's proprietary Accum technology. A cancer vaccine derived from dendritic cells, a protein-based vaccine against Covid-19, and antibody-drug conjugates (ADC) against cancer that deliver the drug directly into the affected cells.

The Accum technology mentioned above enables full scalability of vaccine development for multiple diseases. In tests, 10-fold drug delivery was observed compared to other approved ADC providers. Thus, the Accum platform is an ideal partner for drug treatments. In contrast to radiation therapy, which also attacks healthy cells, Accum therapy only targets the affected cells. As a result, side effects can be significantly reduced.

The second pillar of Defence Therapeutics is vaccine development. There are numerous potential areas of application for which the patented Accum technology can be used. The platform makes it possible to target the latest viruses and thus combat diseases efficiently. The Company has had initial success in a study on mice. 70% of the mice could be cured despite existing tumors. The share has climbed steeply since its stock market debut on May 7. At the opening, the stock was trading at CAD 1.75 and rose to CAD 7.80. Since then, the stock has been consolidating.

Siemens Healthineers - Ahead of the quarterly figures

When the acquisition of US Company Varian Medical Systems for USD 16.4 billion was announced in August 2020, the stock first went on a downward slide. Fears were rife that the Company had paid too much. In the meantime, the wind has changed and new all-time highs have been reached. That's partly due to Covid-19's rapid antigen tests, which have brought in about EUR 750 million in revenue this fiscal year (which ends Sept. 30). Quarterly results are due out on July 30, and more than a few analysts expect the Company to raise its guidance for the current fiscal year.

The other part of the growth is generated by Varian Medical Systems, as this acquisition has opened up various synergies. The California-based Company specializes in the development of novel cancer screening and treatments. The Company has a 45% market share in hardware and software for cancer medicine. Siemens Healthineers can now cover the entire range of early cancer diagnostics, a competitive advantage, especially in hospital sales. The high margins in cancer care mean that further growth is likely.

To better focus sales, a sale of the ultrasound equipment division is said to be under discussion. The share has been on an upward trend since the end of October 2020. Inclusion in the new DAX 40 beckons as a reward. Should this succeed, the share would come more into focus, and more investors could jump on board. Currently, one should wait for the figures at the end of July and then think about an investment. The stock has already moved over 20% in the last month and a half and has not yet consolidated.


All three companies are trying to put a stop to cancer. Due to the high margins, investors can expect large profits in the event of a breakthrough. With biotech companies, one must always expect temporary setbacks. BioNTech has already proven that it is possible to make enormous profits with new technologies. Defence Therapeutics has a very exciting approach that you can invest in before the breakthrough. Siemens Healthineers is focusing more on early detection and can also generate good profits with this.


Author

Armin Schulz

Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

27. July 2021 | 13:01 CET | by Stefan Feulner

BioNTech, XPhyto Therapeutics, MorphoSys - Here we go again

  • Biotechnology

The numbers of new SARS-CoV-2 infections in Germany are rising again, albeit still at a relatively low level. Due to the spread of the Delta variant, Health Minister Jens Spahn warns of incidences beyond the 800 mark as early as this fall. In addition to masking and spacing, the issues surrounding vaccines against the various mutations and regular, reliable testing are returning to the front pages of the news pages.

Read

26. July 2021 | 13:55 CET | by Carsten Mainitz

BioNTech, Cardiol Therapeutics, CureVac - What is next?

  • Biotechnology

Are you smiling or shaking your head? Both are easily understandable reactions that investors might have in light of the latest statements from the Deutsches Aktien Institut (DAI). The DAI calls for better conditions for IPOs of growth companies to prevent such companies from migrating to foreign stock exchanges, as happened with BioNTech, among others. "Especially companies with specialized business models and high financing needs are dependent on foreign investors," explained Uta-Bettina von Altenbockum. However, this is not a new phenomenon either. Other countries have been creating better framework conditions for corporations and better tax incentives for investors for a long time. Own goal. What opportunities are there?

Read

23. July 2021 | 11:37 CET | by André Will-Laudien

CureVac, XPhyto Therapeutics, BioNTech, NanoRepro - Continuous testing or vaccination or both?

  • Biotechnology

Public confusion reigns. The pandemic seems to be locked in chains over the summer, and the population is happy about initial relief with incidences below 10. But now, the first vacationers are already coming back, partly from risk or mutation areas and have to go for testing again as vaccinated persons. It is often forgotten that even those who have been fully vaccinated can be carriers of the virus and can also fall ill, so it should be clear to everyone that personal protective measures must continue to be kept high. Our life with the COVID virus will last much longer than many want to believe...

Read